94 related articles for article (PubMed ID: 22386665)
1. 3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity.
Fisher MJ; Backer RT; Barth VN; Garbison KE; Gruber JM; Heinz BA; Iyengar S; Hollinshead SP; Kingston A; Kuklish SL; Li L; Nisenbaum ES; Peters SC; Phebus L; Simmons RM; van der Aar E
Bioorg Med Chem Lett; 2012 Apr; 22(7):2514-7. PubMed ID: 22386665
[TBL] [Abstract][Full Text] [Related]
2. From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-beta-carbolines: a new class of orally bioavailable mGluR1 antagonists.
Di Fabio R; Micheli F; Alvaro G; Cavanni P; Donati D; Gagliardi T; Fontana G; Giovannini R; Maffeis M; Mingardi A; Tranquillini ME; Vitulli G
Bioorg Med Chem Lett; 2007 Apr; 17(8):2254-9. PubMed ID: 17276684
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.
Zheng GZ; Bhatia P; Daanen J; Kolasa T; Patel M; Latshaw S; El Kouhen OF; Chang R; Uchic ME; Miller L; Nakane M; Lehto SG; Honore MP; Moreland RB; Brioni JD; Stewart AO
J Med Chem; 2005 Nov; 48(23):7374-88. PubMed ID: 16279797
[TBL] [Abstract][Full Text] [Related]
5. [Research progress of selective mGluR1 antagonists].
Yang YL; Sun W; Peng C; Zhang XY; Yang XH
Yao Xue Xue Bao; 2011 Oct; 46(10):1167-72. PubMed ID: 22242445
[TBL] [Abstract][Full Text] [Related]
6. Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity.
Spanka C; Glatthar R; Desrayaud S; Fendt M; Orain D; Troxler T; Vranesic I
Bioorg Med Chem Lett; 2010 Jan; 20(1):184-8. PubMed ID: 19931453
[TBL] [Abstract][Full Text] [Related]
7. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Biswas K; Li A; Chen JJ; D'Amico DC; Fotsch C; Han N; Human J; Liu Q; Norman MH; Riahi B; Yuan C; Suzuki H; Mareska DA; Zhan J; Clarke DE; Toro A; Groneberg RD; Burgess LE; Lester-Zeiner D; Biddlecome G; Manning BH; Arik L; Dong H; Huang M; Kamassah A; Loeloff R; Sun H; Hsieh FY; Kumar G; Ng GY; Hungate RW; Askew BC; Johnson E
J Med Chem; 2007 May; 50(9):2200-12. PubMed ID: 17408249
[TBL] [Abstract][Full Text] [Related]
8. Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.
Hao J; Dehlinger V; Fivush AM; Rudyk HC; Britton TC; Hollinshead SP; Vokits BP; Clark BP; Henry SS; Massey SM; Peng L; Dressman BA; Heinz BA; Roberts EF; Bracey-Walker MR; Swanson S; Catlow JT; Love PL; Tepool AD; Peters SC; Simmons RM; Iyengar S; McKinzie DL; Monn JA
Bioorg Med Chem Lett; 2013 Mar; 23(5):1249-52. PubMed ID: 23374867
[TBL] [Abstract][Full Text] [Related]
9. Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.
Zheng GZ; Bhatia P; Kolasa T; Patel M; El Kouhen OF; Chang R; Uchic ME; Miller L; Baker S; Lehto SG; Honore P; Wetter JM; Marsh KC; Moreland RB; Brioni JD; Stewart AO
Bioorg Med Chem Lett; 2006 Sep; 16(18):4936-40. PubMed ID: 16809035
[TBL] [Abstract][Full Text] [Related]
10. 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
Tehrani LR; Smith ND; Huang D; Poon SF; Roppe JR; Seiders TJ; Chapman DF; Chung J; Cramer M; Cosford ND
Bioorg Med Chem Lett; 2005 Nov; 15(22):5061-4. PubMed ID: 16183275
[TBL] [Abstract][Full Text] [Related]
11. 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.
Roppe JR; Wang B; Huang D; Tehrani L; Kamenecka T; Schweiger EJ; Anderson JJ; Brodkin J; Jiang X; Cramer M; Chung J; Reyes-Manalo G; Munoz B; Cosford ND
Bioorg Med Chem Lett; 2004 Aug; 14(15):3993-6. PubMed ID: 15225713
[TBL] [Abstract][Full Text] [Related]
12. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A; Suzuki G; Maehara S; Hikichi H; Murai T; Murai T; Kawagoe-Takaki H; Hata M; Ito S; Ozaki S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2009 Jul; 330(1):179-90. PubMed ID: 19359526
[TBL] [Abstract][Full Text] [Related]
13. Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists.
Kamenecka TM; Bonnefous C; Govek S; Vernier JM; Hutchinson J; Chung J; Reyes-Manalo G; Anderson JJ
Bioorg Med Chem Lett; 2005 Oct; 15(19):4350-3. PubMed ID: 16039855
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists.
Mantell SJ; Gibson KR; Osborne SA; Maw GN; Rees H; Dodd PG; Greener B; Harbottle GW; Million WA; Poinsard C; England S; Carnell P; Betts AM; Monhemius R; Prime RL
Bioorg Med Chem Lett; 2009 Apr; 19(8):2190-4. PubMed ID: 19289283
[TBL] [Abstract][Full Text] [Related]
15. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
Ornstein PL; Bleisch TJ; Arnold MB; Kennedy JH; Wright RA; Johnson BG; Tizzano JP; Helton DR; Kallman MJ; Schoepp DD; Hérin M
J Med Chem; 1998 Jan; 41(3):358-78. PubMed ID: 9464367
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of aryl isoxazole derivatives as metabotropic glutamate receptor 1 antagonists: a potential treatment for neuropathic pain.
Cho GH; Kim T; Son WS; Seo SH; Min SJ; Cho YS; Keum G; Jeong KS; Koh HY; Lee J; Pae AN
Bioorg Med Chem Lett; 2015 Mar; 25(6):1324-8. PubMed ID: 25677662
[TBL] [Abstract][Full Text] [Related]
17. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
Pietraszek M; Gravius A; Schäfer D; Weil T; Trifanova D; Danysz W
Neuropharmacology; 2005 Jul; 49(1):73-85. PubMed ID: 15992582
[TBL] [Abstract][Full Text] [Related]
18. N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.
Wei Z; Yang H; Liu Z; Tremblay M; Johnstone S; Béha S; Yue SY; Srivastava S; Tomaszewski MJ; Brown W; Walpole C; St-Onge S; Lessard E; Archambault AJ; Groblewski T; Pagé D
Bioorg Med Chem Lett; 2012 Jun; 22(12):3884-9. PubMed ID: 22607668
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G; Kimura T; Satow A; Kaneko N; Fukuda J; Hikichi H; Sakai N; Maehara S; Kawagoe-Takaki H; Hata M; Azuma T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2007 Jun; 321(3):1144-53. PubMed ID: 17360958
[TBL] [Abstract][Full Text] [Related]
20. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC
Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
